Pancreatic islet cells normally secrete insulin in response to high levels of glucose in the blood to maintain steady levels. Type 1 diabetes is an autoimmune disease in which the insulin secreting islet cells are destroyed. Administering insulin is life-saving but does not truly mimic the body's natural response to blood glucose and can result in serious complications such as diabetic retinopathy, nephropathy and neuropathy... Geron Corporation's Press Release -
Blog Archive
-
▼
2008
(233)
-
▼
October
(15)
- Geron Scientists and Collaborators : Activity of P...
- BioLife Solutions : HypoThermosol Adopted by Micro...
- Convincing results of Solianis’ multisensor system...
- Phenomix and Forest : Collaboration on Development...
- Amylin and Lilly : Supply Agreement for Exenatide ...
- Novo Nordisk Assigns Inhaled Insulin Patent Portfo...
- Echo Therapeutics : Issuance of New Patent for Sym...
- Hospira : EndoTool from MD Scientific
- RXi Pharmaceuticals : Exclusive Worldwide License ...
- DIAGNOS : New CARA (Computer Aided Retinal Analysi...
- Array BioPharma : Positive Preclinical Data on Its...
- Oxygen Biotherapeutics : License Agreement for Its...
- Biocon : Human Clinical Data on IN-105 (Oral Insul...
- DexCom : JDRF Study Results Show Continuous Glucos...
- Major Study Reinforces the Power of Medtronic Devi...
-
▼
October
(15)
Thursday, October 30, 2008
Geron Scientists and Collaborators : Activity of Pancreatic Islet-like Cells Derived from Human Embryonic Stem Cells in Diabetes
October 28, 2008 - Geron Corporation (Nasdaq: GERN) announced the publication of data showing the successful engraftment of human embryonic stem cell (hESC)-derived pancreatic islet-like clusters (ILCs) in diabetic mice. After transplantation, the ILCs continued to express important pancreatic islet proteins, responded to high levels of glucose in the blood, and extended the survival of recipient animals.